Health Library · Safety & Side Effects
Cytokine Release Syndrome (CRS): Symptoms, Grading and Management
Educational patient guide · Updated 2026
Cytokine release syndrome (CRS) is one of the most important side effects associated with CAR-T cell therapy. It is also one of the best understood. Knowing what CRS is, when it typically appears, how severity is graded, and how it is treated helps patients and families feel more prepared during the monitoring period after infusion.
This article explains CRS in clear language. It is educational only and does not replace the instructions given by the treating clinical team.
What is cytokine release syndrome?
After CAR-T cells are infused, they can become highly activated when they encounter their target (often CD19 on B-cell cancers). This activation leads to the release of signaling proteins called cytokines. In some patients the cytokine release is strong enough to cause a systemic inflammatory response known as cytokine release syndrome.
CRS is therefore a consequence of the therapy working intensely — not a random unrelated illness. The challenge is that the same immune activation that attacks the cancer can temporarily make the patient feel very unwell and, in higher grades, can affect blood pressure, breathing and organ function.
When does CRS usually occur?
Most cases of CRS begin within the first days to about two weeks after CAR-T infusion. The exact timing varies by product, disease burden and individual patient factors. This is one reason patients remain under close observation in the hospital (or in a closely monitored setting) after receiving the cells.
Early recognition is important. Care teams monitor temperature, heart rate, blood pressure, oxygen levels and laboratory markers so that treatment can be started promptly if CRS develops.
Common symptoms
Symptoms range from mild flu-like illness to more serious systemic effects. Common features include:
- Fever (often the earliest and most frequent sign)
- Fatigue and general malaise
- Muscle or joint aches
- Headache
- Nausea or loss of appetite
- Low blood pressure
- Faster heart rate
- Difficulty breathing or low oxygen levels in more significant cases
Not every patient experiences all of these symptoms. Mild CRS may involve only fever and fatigue; higher-grade CRS involves more pronounced cardiovascular or respiratory effects.
How CRS severity is graded
Clinicians use standardized grading systems (commonly based on ASTCT criteria) to describe the severity of CRS. A simplified overview:
| Grade | Typical features |
|---|---|
| Grade 1 | Fever; mild symptoms that do not require oxygen or blood-pressure support |
| Grade 2 | Fever with mild to moderate low blood pressure responsive to fluids, and/or mild oxygen requirement |
| Grade 3 | More significant low blood pressure requiring medications (vasopressors), and/or higher oxygen needs |
| Grade 4 | Life-threatening instability requiring strong support (for example high-dose vasopressors and/or mechanical ventilation) |
Grading helps the team decide how intensively to treat and monitor. Many patients experience only low-grade CRS; higher grades are less common but require rapid, experienced management.
How hospitals manage CRS
Management is guided by grade, speed of progression and the patient’s overall condition. Typical approaches include:
- Supportive care — fluids, fever control, oxygen, careful monitoring of organs and laboratories
- Tocilizumab — an interleukin-6 (IL-6) receptor blocker frequently used for CRS that reaches a threshold requiring specific therapy
- Corticosteroids — used when CRS is more severe, progressive, or not responding adequately to tocilizumab alone
- Intensive care support — for higher-grade CRS, including blood-pressure medications and respiratory support if needed
Centers experienced in cellular therapy keep these medicines and protocols immediately available. The goal is to control the inflammatory response while allowing the CAR-T cells to continue their anti-cancer activity as much as possible.
Why center experience matters
CRS is manageable in the large majority of cases when recognized early and treated according to established protocols. This is one of the main reasons CAR-T infusion and the early post-infusion period are handled in hospitals prepared for cellular therapy — with access to intensive care, rapid laboratory testing and staff trained in these specific toxicities. In the technology-transfer pathway linked to Biruni Cell Therapy, clinical administration and monitoring are organized through specialized hospital settings with access to this manufacturing route.
CRS is not the same as infection
Fever after CAR-T can be caused by CRS, by infection, or sometimes by both. Care teams therefore investigate for infection (cultures, imaging and other tests as needed) while also treating possible CRS. Patients should never assume that fever is “only CRS” or “only infection” — the medical team makes that distinction based on the full clinical picture.
What patients and families can do
- Report fever, breathing difficulty, dizziness, confusion or any sudden change in condition immediately to the care team
- Know who to call after discharge and which symptoms require urgent return to the hospital
- Follow infection precautions as instructed, because low blood counts and immune effects can continue after CRS resolves
- Ask the team in advance what their CRS protocol looks like and which medicines they use first-line
Key points to remember
- CRS is a known and expected risk of CAR-T therapy caused by intense immune activation
- It most often appears in the first days to two weeks after infusion
- Severity is graded; many cases are low grade and manageable
- Standard treatments (supportive care, tocilizumab, corticosteroids, intensive care when needed) are well established
- Early recognition and an experienced treating center are the most important safety factors
For the broader sequence of treatment steps, see How Does the CAR-T Cell Therapy Process Work Step by Step?